POLYMER FACTORY

Interim Report Q2

Second quarter, April-June 2026

- Polymer Factory Highlights Shimadzu Application News Featuring SpheriCal® Calibrants on MALDI-8020
- The company Participated at ASMS 2026 in San Diego from May 31 to June 4
- Polymer Factory Enters Material Transfer Agreement with Thermo Fisher Scientific

Year to date, January-June 2026

- Polymer Factory will act as a sponsor of the 13th International Dendrimer Symposium (IDS13), which will be organized by KTH Royal Institute of Technology and held in Stockholm from September 30 to October 2, 2026
- The Company participated as an exhibitor with its own booth at ANALYTICA 2026, held in Munich from March 24 to March 27, 2026
- SpheriCal® Calibration Platform Represents a Strategically Attractive Growth Opportunity
- Polymer Factory's Dendritic Polymers Demonstrate Strong Antimicrobial Performance in Advanced Fiber Membranes
- Polymer Factory Sweden AB (publ) carries out directed share issues totaling SEK 2.28 million

Key Figures

	Second quarter		Six months	
(KSEK)	Apr-Jun 2026	Apr-Jun 2025	Jan-Jun 2026	Jan-Jun 2025
Net sales	419	903	722	1,251
Profit (loss) for the period	-451	-165	-1,796	-1,045
Total assets	5,541	5,905	5,541	5,905
Equity / assets ratio (%)	83	66	83	66
Cash flow for the period	-572	-431	-9	-85
Basic earnings per share (SEK)	-0.02	-0.01	-0.10	-0.08

COMMENTS FROM CEO MATS WALLNÉR

The second quarter was characterized by continued strong interest in Polymer Factory's products from leading international organizations

" Well positioned to create long-term value for our customers, partners and shareholders"

Mats Wallnér, CEO of Polymer Factory

Strengthening our commercial position

The second quarter was characterized by continued strong interest in Polymer Factory's products from leading international organizations. During the quarter, we initiated several commercial collaborations with multinational companies that recognize the significant value our technologies can deliver to their customers.

Although the global market continues to be affected by geopolitical uncertainty, macroeconomic challenges and cautious investment decisions, we are seeing encouraging momentum in our commercial discussions.

Strategic collaborations driving future growth

A major achievement during the quarter was the initiation of a strategic collaboration with Thermo Fisher Scientific in the United States regarding our innovative SpheriCal® technology. Thermo Fisher Scientific recognizes the commercial potential of our calibration products for enabling new applications in advanced multidimensional mass spectrometry. In addition, several other multinational companies have expressed strong interest in the same technology area, reinforcing our confidence in the long-term commercial potential of SpheriCal®.

Global customers validate our technology

Our Dendrimers & Dendrons business continues to develop positively. During the quarter, Polymer Factory supplied products to several leading international companies and world-renowned academic institutions. Customers included GSK, Ascendis Pharma, Merck, STEMCELL Technologies, the Massachusetts Institute of Technology (MIT) and Princeton University.

The continued confidence shown by these organizations demonstrates the quality, performance and competitiveness of our technologies and products.

Promising progress in drug delivery research

Development of our Dendritic Nanogels (DNG) continues to demonstrate significant potential as advanced drug delivery systems for difficult-to-treat cancers, including glioblastoma and triple-negative breast cancer.

Results from the collaborative research published in 2025 demonstrated promising performance of our patented bis-MPA dendritic nanotechnology, including high drug-loading capacity, efficient tumor penetration and significant inhibition of cancer cell growth in laboratory studies. During the second half of 2026, the research team plans to repeat the laboratory studies to further validate these encouraging results and support the next stages of development.

Well positioned for the future

Polymer Factory is built on decades of world-class research and expertise in dendritic materials and advanced polymer technologies. Today, we are supplying products to some of the world's leading companies and research institutions while continuing to expand our commercial opportunities through strategic partnerships and product innovation.

MATS WALLNÉR
CEO

ABOUT POLYMER FACTORY

Polymer Factory is a leading developer and provider of dendritic nanomaterials, to be applied over a range of sectors globally.

Polymer Factory is in many ways an accelerator firm for dendritic nanotechnology – generating cutting-edge products desired by customers across different high-demand sectors. From our roots in dendritic materials, we have developed SpheriCal®, a pioneering calibration technology for mass spectrometry (MS), and more recently, our latest addition, DNGs. Our broad portfolio, comprising more than 300 products, has attracted customers from BigPharma, MedTech, BioTech, as well as the chemical and other industries.

Stemming from many years of cutting-edge research, Polymer Factory was founded by a team of well-renowned scientists. This research has evolved into a business that provides products to billion dollar industries.





MISSION

To provide life science customers with premium precision nanomaterials for improved analysis and performance.

VISION

By providing nanomaterials, enable the development of products that improve life and prosperity.

What makes dendritic materials so special, and in many ways superior, is their flawlessness, multifunctionality and dynamic structure. This makes them ideal for a vast number of applications in an array of industrial uses, from applications within pharmaceuticals and diagnostics as well as the chemistry and material industries. Polymer Factory's dendritic materials have a number of competitive advantages:

- Structural perfection (i.e. they are monodisperse and structurally flawless).
- High scalability and batch-to-batch consistency – an important feature across several high-end sectors e.g. therapeutic and diagnostic applications.
- High loading capacity, enabling the attachment of an exact and large number of drugs while decreasing the drug's toxicity when merged with the dendritic material.
- High level of optimization and flexibility, allowing users to achieve desired targeted complexation and product formulation.
- Biocompatibility and biodegradability; the dendritic carriers degrade under physiological conditions.



For more information about Polymer Factory Sweden AB and our products, visit http://www.polymerfactory.com

EVENTS DURING Q2 2026

KEY EVENTS DURING THE PERIOD

Polymer Factory Enters Material Transfer Agreement (MTA) with Thermo Fisher Scientific.

KEY EVENTS AFTER THE END OF THE PERIOD

Polymer Factory has joined LIMMIC, a German innovation project developing a universal standard for calibrating multidimensional mass spectrometry data.

RELATED PARTY TRANSACTIONS

There is a consultancy agreement between the Company and NORDICBLUE AB, which is partly owned by Mats Wallnér, regarding services related to his role as CEO for the Company. During Q2, a total of SEK 80,290 has been invoiced under the agreement.
There is also a consultancy agreement between the Company and SCEM Consulting AB, which is partly owned by Michael Malkoch, regarding services related to his role as CTO for the Company. During Q2, a total of SEK 80,290 has been invoiced under the agreement.

RISKS AND UNCERTAINTY FACTORS

Polymer Factory is exposed to various types of risks, which can be categorized as related to business and operations, industry and market, intellectual property, and financial risks. During the second quarter, it is assessed that no significant changes has occured in respect of risks and uncertainties.

More details on the Company's risks and uncertainties are described in the Annual Report that was published on 2026-03-27 which can be found on the company's website.

ORGANIZATION

As per June 30, 2026, the number of employees in the company was 3, in addition to above mentioned consultancy agreement.

SHARE

Polymer Factory Sweden AB (publ) is listed on Nordic SME on Nordic Growth Market since June 24, 2024 under ticker POLYMER. The Company was previously listed on Spotlight Stock Market since April 7, 2021 under the same ticker.

Total number of shares amounts to 19,967,395.

Nordic Growth Market NGM AB, owned by Börse Stuttgart, is a Swedish stock exchange with permission from the Swedish Financial Supervisory Authority to operate a regulated market, Main Regulated, a multilateral trading platform, Nordic MTF, and a growth market for small and medium-sized companies, Nordic SME.

ACCOUNTING PRINCIPLES

The interim report is prepared in accordance with the Swedish Annual Accounts Act and the standards of the Swedish Accounting Standards Board (BFNAR 2012:1) (K3). Accounting principles are unchanged compared with 2024.

This report has not been reviewed by the company's auditor.

OTHER INFORMATION

A warrant program for the CEO and other employees was established on the extra general meeting on 20 December 2021. More information on the program and terms can be found on the Company's website.

FINANCIAL OVERVIEW

REVENUES

Net sales for the period amounted to KSEK 419 (903), a decrease with 53% compared to Q2 2025. Net sales for year to date amounted to KSEK 722 (1,251), a decrease with 42% compared to the same period 2025.

During the quarter there was a minimal decrease in inventories. Other revenue amounted to KSEK 504 (504) for the period, and KSEK 504 (1,003) for year to date, which is derived from work performed under the grant from EDF.

Out of the four segments (Dendrimers and dendrons, Hyperbranched materials, SpheriCal® and DNG), SpheriCal® and Dendrimers and Dendrons was predominent in Q2 as well as year to date. North America and Europe has been the predominent markets during both periods.

OPERATING EXPENSES

Total operating expenses amounted to KSEK 1,371 (1,571) for Q2 and KSEK 3,016 (3,397) for year to date respectively.

RESULT

Loss amounted to KSEK -451 (-165) for the second quarter, and KSEK -1,796 (-1,045) for year to date.

Earnings per share amounted to SEK -0.02 (-0.01) for the second quarte and SEK -0.10 (-0.08) for year to date.

CASH FLOW AND FINANCIAL POSITION

Cash flow from operating activities for the period was KSEK -572 (-431) and KSEK -2,284 (-1,591) for year to date.

Cash flow for the period was KSEK -572 (-431) and for year to date KSEK -9 (-85),. As per June 30, 2026 Cash and bank amounted to KSEK 1,706 (1630) and equtiy amounted to 4,606 (3,924).

The board assesses that there is a risk that the company will not have sufficient financing for the next 12 months given that sales do not develop favorably, cost reductions are not sufficient and/or that no capital is obtained from the capital market.







INCOME STATEMENT IN SUMMARY

(KSEK)	Second quarter APR-JUN 2026	Second quarter APR-JUN 2025	Six months JAN-JUN 2026	Six months JAN-JUN 2025	Full year FULL YEAR 2025
Revenue					
Net sales	419	903	722	1,251	1,990
Change in inventories of products in progress, finished goods and work in progress	-3	-2	-9	98	66
Other revenue	504	504	507	1,003	1,834
Total revenue, inventory changes, etc.	**920**	**1,406**	**1,220**	**2,352**	**3,890**
Operating expenses					
Goods for resale	-21	-33	-78	-58	-135
Other external expenses	-786	-838	-1,674	-1,672	-3,448
Staff costs	-471	-595	-1,075	-1,462	-2,807
Depreciation of fixed assets	-92	-92	-185	-185	-369
Other operating expenses	-1	-13	-4	-20	-29
Total operating expenses	**1,371**	**1,571**	**-3,016**	**-3,397**	**-6,788**
Operating profit/loss	***-451***	***-165***	***-1,796***	***-1,045***	***-2,898***
Financial items					
Interest expenses and similar items	0	0	0	0	2
Total financial items	**-**	**-**	**-**	**-**	**2**
Total after financial items	**-451**	**-165**	**-1,796**	**-1,045**	**-2,896**
Profit/loss before taxes	***-451***	***-165***	***-1,796***	***-1,045***	***-4,118***
Taxes					
Tax on profit/loss for the period	-	-	-	-	-
Profit/loss for the period	***-451***	***-165***	***-1,796***	***-1,045***	***-4,118***

BALANCE SHEET

(KSEK)	30 JUNE 2026	30 JUNE 2025	31 DECEMBER 2025
ASSETS			
Fixed assets			
Intangible fixed assets	408	525	467
Tangible fixed assets	1,301	1,554	1,427
Total fixed assets	**1,709**	**2,079**	**1,894**
Current assets			
Inventory	1,575	1,616	1,584
Current receivables	551	580	423
Cash and bank	1,706	1,630	1,715
Total current assets	**3,832**	**3,826**	**3,722**
TOTAL ASSETS	**5,541**	**5,905**	**5,616**
EQUITY AND LIABILITIES			
Equity			
Equity	6,402	4,969	7,022
Result of the period	-1,796	-1,045	-2,896
Total equity	**4,606**	**3,924**	**4,126**
Liabilities			
Current liabilities	935	1,981	1,490
Total liabilities	**935**	**1,981**	**1,490**
TOTAL EQUITY AND LIABILITIES	**5,541**	**5,905**	**5,616**

CASH FLOW STATEMENT

(KSEK)	APR-JUN 2026	APR-JUN 2025	JAN-JUN 2026	JAN-JUN 2025	FULL YEAR 2025
	Second quarter		Six months		Full year
Operating activities					
Cash flow from operating activities	-572	-431	-2,284	-1,591	-3,559
Cash flow from operating activities	**-572**	**-431**	**-2,284**	**-1,591**	**-3,559**
Investing activities					
Cash flow from investing activities	-	-	-	-	-
Cash flow from investing activities	**-**	**-**	**-**	**-**	**-**
Financing activities					
Cash flow from financing activities		-	2,275	1,506	3,559
Cash flow from financing activities	**-**	**-**	**2,275**	**1,506**	**3,559**
Cash flow for the period	***-572***	***-431***	***-9***	***-85***	***0***
Bank					
Bank opening	2,278	2,061	1,715	1,715	1,715
Bank closing	1,706	1,630	1,706	1,630	1,715

CHANGES IN EQUITY

	SHARE CAPITAL	NON-REGISTERED SHARE CAPITAL	SHARE PREMIUM RESERVE	PROFIT BROUGHT FORWARD	PROFIT FOR THE PERIOD	TOTAL
2024-12-31	**1,070**		**16,598**	**-10,087**	**-4,118**	**3,463**
Disposition according to AGM				-4,118	4,118	0
New share issue	274		1,232			1,506
Loss for the period					-1,045	-1,045
2025-06-30	**1,344**		**17,830**	**-14,205**	**-1,045**	**3,924**
New share issue	274		1,779			2,053
Loss for the period					-1,851	-1,851
2025-12-31	**1,618**		**19,609**	**-14,205**	**-2,896**	**4,126**
New share issue	379		1,896			2,275
Disposition according to AGM				-2,896	2,896	0
Loss for the period					-1,796	-1,796
2026-06-30	**1,997**		**21,505**	**-17,101**	**-1,796**	**-4,605**

The Board of Directors and the CEO assure that this interim report gives a true and fair view of the company's operations, position and results and describes significant risks and uncertainties that the company is facing.

This report has not been reviewed by the company's auditor.

This disclosure contains information that Polymer Factory is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 18 August 2026.

Stockholm 2026-08-18
CEO, Mats Wallnér

COMPANY INFORMATION

Company name
Polymer Factory Sweden AB (PUBL)

Organizational number
556695-9531

Address
Teknikringen 48,
114 28 Stockholm, Sweden

Phone
+46 70-321 14 15

Website
www.polymerfactory.com

CALENDAR

Current financial year:	2026-01-01 – 2026-12-31
Half-year Report (Q2):	2026-08-18
Quarterly Report (Q3):	2026-11-17
Quarterly Report (Q4):	2027-02-16

CONTACT

CEO
Mats Wallnér

E-mail
mats.wallner@polymerfactory.com

Phone
+46 70 951 95 06

POLYMER FACTORY

WWW.POLYMERFACTORY.COM